Search results
Diabetic ketoacidosis (DKA) is a frequent and potentially life-threatening complication of type 1 diabetes. Though preventable and despite advances in monitoring technologies, insulin therapeutics and insulin delivery systems, the rates of both community and hospital acquired DKA remain largely unchanged. Although mortality today is relatively
- Correct ketosis and acidosis with continuous insulin - Replace electrolyte deficits* - Replace free water deficit* - Prevent hypoglycemia - Determine inciting condition for the DKA - Correct hyperglycemia (secondary goal) - When DKA resolved: begin appropriate SQ insulin before stopping Insulin drip PATHOPHYSIOLOGY Acidemia Osmotic Diuresis
Once drip is discontinued, give first dose of subcutaneous insulin 1 hour before infusion is stopped. 5. See FAQ page of Nomogram for answers to frequent asked questions.
22 maj 2020 · This is a subcutaneous (SubQ) insulin protocol that replaces insulin drip needs for mild to moderate DKA. Procedures are adapted for COVID-related considerations of minimizing risk to staff while optimizing patient safety and health.
Appropriate patients in DKA will be admitted to general medicine floor teams and managed by the endocrinology consulting team using the following subcutaneous (SC) protocol. Rule Out: Pregnancy, Drug use (especially cocaine and methamphetamines), thyrotoxicosis, infection, “spoiled” insulin, myocardial infarction, and other causes of DKA.
The focus of management of DKA is on restoring hydration, clearing ketones, correcting electrolyte losses and normalising blood glucose level. DEFINITION AND DIAGNOSIS OF DKA Triad of 1. Blood ketones ≥ 3.0 mmol/L or urine ketones ≥ 2+ on dipsticks. 2. Blood glucose >11.0 mmol/L or known diabetes mellitus . 3. Bicarbonate (HCO
Document in special instructions section of the IV insulin order form that the patient is on DKA protocol. Use any soluble insulin eg: Actrapid, Humulin R. Concentration should be 50 units of insulin in 49.5mL 0.9% sodium chloride through a syringe driver. Step 4 - Continuation of intravenous insulin Long acting (basal) subcutaneous insulin can be
